Category: News

  • Why GLP-1 drugs won’t replace insulin in diabetes care

    Why GLP-1 drugs won’t replace insulin in diabetes care

    Why GLP-1 drugs won’t replace insulin in diabetes care

    GLP-1 drugs are revolutionizing diabetes treatment, but does their success mean insulin’s days are numbered? Not even close. While these breakthrough therapies are transforming blood sugar management and weight loss, millions of patients will continue to depend on insulin to survive. Deenadayalan Bakthavatsalam, CEO of rBIO, explains why insulin remains indispensable, what the GLP-1 boom means for the future of diabetes care, and why making insulin more affordable and accessible is as important as ever.


    GLP-1 medicines have changed the conversation around diabetes and obesity. Drugs in this class help the body release more insulin when blood sugar is high, reduce glucagon, slow stomach emptying, and reduce appetite. For many people with type 2 diabetes, this can mean better glucose control and weight loss, generally with a low risk of hypoglycemia when these medicines are used without insulin or certain other glucose-lowering drugs.

    This is a major scientific and clinical advance. It has also led some investors to question whether insulin will still be needed. But it does not make insulin obsolete.

    The reason is simple: GLP-1 medicines work by helping the body use its own insulin system more effectively. They depend on functioning pancreatic beta cells. In early or moderate type 2 diabetes, many patients still have enough beta-cell function for GLP-1 therapy to work well. But as diabetes progresses, beta-cell function can decline. When the body can no longer produce enough insulin, patients with type 2 diabetes still need insulin therapy.

    For people with type 1 diabetes, insulin is not optional. Their immune system destroys the beta cells that produce insulin. Without insulin replacement, blood sugar can rise dangerously, leading to diabetic ketoacidosis, coma, and death. GLP-1 medicines may have supporting roles in selected patients, but they cannot replace the missing hormone.

    Insulin acts quickly and directly on the body’s cells to lower blood sugar and thus remains essential in hospitals, emergency care, pregnancy-related diabetes, severe hyperglycemia, diabetic ketoacidosis, and advanced insulin-deficient type 2 diabetes. In these settings, insulin is not just another diabetes drug; it is a life-saving hormone.

    For investors and healthcare leaders, the message is clear. GLP-1 drugs are expanding the metabolic-health market, but they do not eliminate the need for insulin. Instead, they highlight the growing global demand for better diabetes care. Insulin remains one of the most clinically validated, indispensable, and globally needed biologic medicines.

    This continuing need reinforces rBIO’s mission to develop a more cost-efficient insulin manufacturing process and license that technology to manufacturing partners worldwide.

    Dr. Judith Shizuru, co-founder of Jasper Therapeutics, now Kira Pharmaceuticals, and member of rBIO’s board of directors, stated: “The rapid spread of diabetes worldwide represents a significant unmet medical need.”

    The future of diabetes treatment will not be a choice between GLP-1 therapies and insulin. Both will continue to play important, and sometimes complementary, roles. GLP-1 therapies improve metabolic control for many patients, while insulin remains the foundation for those who cannot produce enough of it.

    Affordable, reliable insulin access is still a global healthcare priority.


    (1) American Diabetes Association’s Standards of Care in Diabetes 2026.

    ← Back to news

    Contact rBIO for current information →

  • BioPharma APAC: R-biolin matches Novolin R in pre-clinical tests, gears up for 50× scale-up and human trials

    BioPharma APAC: R-biolin matches Novolin R in pre-clinical tests, gears up for 50× scale-up and human trials

    NEWS & MEDIA · February 5, 2025

    BioPharma APAC: R-biolin matches Novolin R in pre-clinical tests, gears up for 50× scale-up and human trials

    This article summarizes coverage published on February 5, 2025.

    BioPharma APAC reports that rBIO’s lead biosimilar insulin candidate, R‑biolin, achieved bioequivalence to Novo Nordisk’s Novolin® R in animal studies—an important validation step that clears the path for a 50‑fold manufacturing scale‑up and the first‑in‑human trials planned for later this year.

    “R‑biolin matched Novolin® R in preclinical studies, validating its potential as a cost‑effective biosimilar insulin.” — BioPharma APAC.

    Read the full article →

    See how rBIO is transforming insulin affordability and access.

    ← Back to news

    Contact rBIO for current information →

  • As major insulin producers shift focus, rBIO steps up to address potential shortages

    As major insulin producers shift focus, rBIO steps up to address potential shortages

    NEWS & MEDIA · February 4, 2025

    As major insulin producers shift focus, rBIO steps up to address potential shortages

    As major insulin producers shift focus, rBIO steps up to address potential shortages

    Company advances R‑biolin scale‑up and first‑in‑human trials to safeguard affordable insulin access.

    With leading insulin manufacturers pivoting toward higher‑margin GLP‑1 and analogue products, supplies of human‑insulin formulations risk further contraction. Houston‑based synbio firm rBIO today announced a 50× manufacturing scale‑up of its biosimilar candidate R‑biolin and plans to initiate human trials in 2H 2025—aiming to avert projected shortages and reduce global costs.

    HOUSTON, February 4, 2025 — Recent price cuts by major insulin manufacturers may appear to address affordability challenges, but they primarily target older insulin drugs nearing patent expiration. This tactic, coupled with the discontinuation of essential insulins like Novo Nordisk Levemir® and a shift in focus towards more profitable GLP-1 drugs, creates a concerning landscape of potential shortages and continued high costs for many patients. 

    rBIO, a biotechnology company committed to improving insulin access and affordability, is stepping up to fill this gap. Today, the company announced the successful completion of preclinical studies for its first biosimilar insulin, R-biolin, demonstrating bioequivalence to Novolin® R.

    “While some celebrate price reductions on older insulins, the reality is that many patients rely on specific formulations that are being phased out or remain prohibitively expensive,” said Cameron Owen, CEO of rBIO. “Our mission is to ensure a stable supply of affordable insulin options, starting with our lead biosimilar, R-biolin, and continuing with our next project, a biosimilar to Levemir.”

    rBIO’s commitment to patient needs is evident in its focus on developing biosimilars for discontinued or less profitable insulins. By leveraging innovative production methods, rBIO aims to offer high-quality alternatives at significantly lower costs, challenging the industry’s status quo and prioritizing patient well-being over profit maximization.

    rBIO achieves scientific milestone in preclinical studies

    A first-in-animal study conducted by Innospec, a leading contract research organization, found that R-biolin exhibits similar efficacy in achieving the primary end point of reducing blood glucose level as Novo Nordisk’s Novolin® R, one of the leading insulin products on the market. This achievement marks a significant step forward in rBIO’s mission to provide affordable insulin to millions of people living with diabetes.

    “The Innospec Bioresearch team observed striking similarities between rBIO’s insulin and the biological function characteristics of Novolin R, a trusted standard in diabetes management. Early lab results suggest that rBIO’s insulin behaves in a highly controlled manner, akin to Novolin, showing promise for comparable efficacy and reliability. Innospec Bioresearch is eager to collaborate further with rBIO, scaling these findings and exploring the potential for broader clinical applications. This partnership could represent a significant step forward in insulin innovation and improved patient outcomes,” said Dr. Viswanathan, director, Innospecs Bioresearch.

    “rBIO has strategically engaged with multiple partners, including CROs and CDMOs, to rigorously validate and ensure the reproducibility of our expression platform technology. The successful biochemical and biological validation achieved through both in vitro and in vivo studies paves the way for commercial scale-up,” said Dr. Deenadayalan Bakthavatsalam, chief scientific officer of rBIO.

    rBIO addresses the insulin shortage

    The recent discontinuation of Levemir by Novo Nordisk has left many patients, particularly pregnant women, children, and athletes who require a longer-acting basal insulin, searching for alternatives. rBIO is actively developing a Levemir biosimilar to address this critical shortage.

    “As a patient advocate, I’m deeply concerned about the industry’s focus on profits over patients,” said Alison Smart, founder of the Alliance to Protect Insulin Choice. “rBIO’s dedication to developing affordable biosimilars offers a much-needed solution to the challenges faced by the diabetes community.”

    “We recognize the urgent need for a Levemir biosimilar and are committed to bringing a product to market as quickly as possible,” added Owen. “Our goal is to ensure that no patient is left without access to the insulin they need. With R-biolin now validated, we are looking for partners to help us achieve scale-up.”

    To learn more about rBIO and its commitment to improving insulin access and affordability, please visit rBIO.com.

    About rBIO

    rBIO is a biotechnology company dedicated to developing and commercializing affordable biosimilars. The company’s innovative manufacturing platform enables efficient and cost-effective production of high-quality biosimilars, beginning with insulin. rBIO is committed to improving the lives of people by making life-saving medications accessible to all. To learn more, visit rBIO.com.

    ← Back to news

    Contact rBIO for current information →

  • FirstWord Pharma: rBIO steps in as big insulin makers scale back legacy products

    FirstWord Pharma: rBIO steps in as big insulin makers scale back legacy products

    NEWS & MEDIA · February 4, 2025

    FirstWord Pharma: rBIO steps in as big insulin makers scale back legacy products

    This article summarizes coverage published on February 4, 2025.

    FirstWord Pharma spotlights a looming supply gap in human‑insulin formulations as major manufacturers pivot to next‑gen analogues. The piece positions rBIO and its biosimilar candidate R‑biolin as timely, lower‑cost relief—especially after animal studies showed bioequivalence to Novolin® R.

    “With Novo Nordisk and Eli Lilly prioritising GLP‑1s, smaller biotech players like rBIO could become critical to averting future shortages of essential insulins,” the article notes.

    Key takeaways

    • Bioequivalence confirmed: Pre‑clinical data demonstrate pharmacokinetic and pharmacodynamic parity with Novolin® R.
    • 50× scale‑up underway: rBIO reports pilot‑plant runs that multiply output fifty‑fold ahead of first‑in‑human trials.
    • Cost advantage: rBIO’s continuous‑fermentation platform aims for a step‑change reduction in cost of goods versus recombinant DNA processes.

    Read the full article →

    See how rBIO is transforming insulin affordability and access.

    ← Back to news

    Contact rBIO for current information →

  • BioProcess Online: The path to producing an insulin biosimilar

    BioProcess Online: The path to producing an insulin biosimilar

    NEWS & MEDIA · July 17, 2024

    BioProcess Online: The path to producing an insulin biosimilar

    This article summarizes coverage published on July 17, 2024.

    In this technical feature, BioProcess Online sits down with rBIO co‑founder Cameron Owen and CSO Dr. Deenadayalan Bakthavatsalam to unpack the real‑world hurdles of turning laboratory success with R‑biolin into metric‑ton commercial output. Their candid discussion gives investors and supply‑chain watchers a rare, inside look at the scale‑up strategy behind one of the few U.S. startups tackling affordable human insulin.

    “Our primary focus right now is getting from pilot batches to several metric tons of insulin per year,” Owen tells BioProcess Online, adding that continuous‑fermentation runs have already demonstrated a 50× yield increase.

    Key takeaways

    • Metric‑ton ambition: rBIO’s target capacity is “several metric tons per year,” a scale rarely attempted by early‑stage biosimilar developers.

    • Continuous‑fermentation edge: Custom bacterial strains and single‑train processing underwrite a projected cost‑of‑goods drop versus legacy recombinant DNA methods.

    • Regulatory runway: With pre‑clinical bioequivalence data in hand, rBIO confirms IND‑enabling studies are underway ahead of first‑in‑human trials.


    Read the full article
    →

    ← Back to news

    Contact rBIO for current information →

  • WIRED: Can a tiny biotech make insulin dirt-cheap?

    WIRED: Can a tiny biotech make insulin dirt-cheap?

    NEWS & MEDIA · February 2, 2024

    WIRED: Can a tiny biotech make insulin dirt-cheap?

    This article summarizes coverage published on February 2, 2024.

    Why this story matters

    WIRED’s in‑depth feature explains how the company’s R‑biolin biosimilar could shake up a century‑old insulin supply chain and drive down costs for the 8 million US insulin‑dependent patients.

    “If rBIO can hit its price targets, the yearly insulin bill for a typical Type‑1 patient could fall from thousands of dollars to mere hundreds,” WIRED writes, noting the company’s planned 50× manufacturing scale‑up and upcoming human trials.

    Key takeaways

    • Cost‑per‑dose target: rBIO aims for sub‑$0.50 production cost through continuous‑fermentation and downstream‑processing innovations.
    • Regulatory path: The team expects to file an IND with the FDA in 2026 after completing GLP toxicology and Phase 1 readiness studies.
    • Market context: As Novo Nordisk and Eli Lilly prioritize GLP‑1 therapies, WIRED frames R‑biolin as a hedge against potential shortages of human insulin formulations.
    • Social impact: The article highlights patient‑advocacy groups pushing for affordable insulin and positions rBIO as an emerging ally.

    Read the full article →

    ← Back to news

    Contact rBIO for current information →